(June 5) Since the Addendum to the April 20, 2020 Brief Overview was published on May 29, 2020, The Lancet retracted an article that had significant impact on the conduct of clinical trials of hydroxychloroquine in the treatment of COVID-19. A review of the latest development and publication is ongoing and a report will be posted shortly.

(May 29) Important new evidence became available since the original Brief Overview on the use of chloroquine or hydroxychloroquine, with or without azithromycin, for treating COVID-19 was posted on the CADTH website on April 20, 2020. This new information indicates that there is still uncertainty regarding the clinical benefit of using these drug regimens for treating patients with COVID-19. It does, however, suggest that there may be potential harm associated with the use of chloroquine or hydroxychloroquine, with or without azithromycin. Some of the new studies have reported the occurrence of QTc prolongation on electrocardiographic readings; QTc prolongation may be associated with increased risk of severe cardiac arrythmia. Some research projects on hydroxychloroquine, including the WHO-sponsored Solidarity trial, have temporarily been halted in order to assess the safety data collected thus far on this drug.

Link to Report

Chloroquine and Hydroxychloroquine, With or Without Azithromycin, for COVID-19: An Addendum to the April 20, 2020 Brief Overview

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.